NASDAQ:GRAL GRAIL (GRAL) Stock Price, News & Analysis $32.79 -1.32 (-3.87%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$32.62 -0.17 (-0.53%) As of 08/29/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About GRAIL Stock (NASDAQ:GRAL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GRAIL alerts:Sign Up Key Stats Today's Range$32.05▼$33.9850-Day Range$31.42▼$51.4252-Week Range$12.33▼$63.99Volume693,949 shsAverage Volume774,663 shsMarket Capitalization$1.18 billionP/E RatioN/ADividend YieldN/APrice Target$31.50Consensus RatingHold Company Overview GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA. Read More GRAIL Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks20th Percentile Overall ScoreGRAL MarketRank™: GRAIL scored higher than 20% of companies evaluated by MarketBeat, and ranked 862nd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.1 / 5Analyst RatingHold Consensus RatingGRAIL has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageGRAIL has received no research coverage in the past 90 days.Read more about GRAIL's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for GRAIL are expected to grow in the coming year, from ($15.15) to ($12.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GRAIL is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GRAIL is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGRAIL has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about GRAIL's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted16.14% of the float of GRAIL has been sold short.Short Interest Ratio / Days to CoverGRAIL has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GRAIL has recently decreased by 12.86%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGRAIL does not currently pay a dividend.Dividend GrowthGRAIL does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted16.14% of the float of GRAIL has been sold short.Short Interest Ratio / Days to CoverGRAIL has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GRAIL has recently decreased by 12.86%, indicating that investor sentiment is improving significantly. News and Social Media2.2 / 5News Sentiment0.93 News SentimentGRAIL has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.11 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for GRAIL this week, compared to 7 articles on an average week.Search InterestOnly 3 people have searched for GRAL on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added GRAIL to their MarketBeat watchlist in the last 30 days. This is a decrease of -77% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, GRAIL insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,780,266.00 in company stock.Percentage Held by InsidersOnly 1.85% of the stock of GRAIL is held by insiders.Read more about GRAIL's insider trading history. Receive GRAL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GRAIL and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GRAL Stock News HeadlinesGRAIL (NASDAQ:GRAL) President Joshua Ofman Sells 4,202 SharesAugust 21, 2025 | insidertrades.comGRAIL: Intriguing Cancer Testing Product Needs More Time And FDA ApprovalAugust 31 at 8:25 AM | seekingalpha.comHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking and savings account… With this better, more technologically advanced dollar. President Trump himself called it a "big innovation"… And said that this new form of currency represents "American brilliance at its best."September 1 at 2:00 AM | Brownstone Research (Ad)GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)August 29 at 4:01 PM | prnewswire.comGRAIL to Present at Morgan Stanley 23rd Annual Global Healthcare ConferenceAugust 26, 2025 | prnewswire.comGRAIL, Inc. (NASDAQ:GRAL) Released Earnings Last Week And Analysts Lifted Their Price Target To US$40.50August 16, 2025 | finance.yahoo.comGrail Inc’s Galleri Test Faces Uncertainty Amid Regulatory Challenges and Rising CompetitionAugust 15, 2025 | msn.comGrail Inc’s Earnings Call Highlights Growth and OptimismAugust 14, 2025 | msn.comSee More Headlines GRAL Stock Analysis - Frequently Asked Questions How have GRAL shares performed this year? GRAIL's stock was trading at $17.85 at the beginning of the year. Since then, GRAL stock has increased by 83.7% and is now trading at $32.79. How were GRAIL's earnings last quarter? GRAIL, Inc. (NASDAQ:GRAL) released its earnings results on Tuesday, August, 12th. The company reported ($3.18) EPS for the quarter, missing the consensus estimate of ($3.14) by $0.04. The firm had revenue of $35.54 million for the quarter, compared to the consensus estimate of $37.57 million. GRAIL had a negative net margin of 329.86% and a negative trailing twelve-month return on equity of 16.64%. Read the conference call transcript. Who are GRAIL's major shareholders? GRAIL's top institutional shareholders include Primecap Management Co. CA (5.71%), AQR Capital Management LLC (3.70%), State Street Corp (3.47%) and Geode Capital Management LLC (2.11%). Insiders that own company stock include Chun R Ding, Robert P Ragusa, Joshua J Ofman and Aaron Freidin. View institutional ownership trends. How do I buy shares of GRAIL? Shares of GRAL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GRAIL own? Based on aggregate information from My MarketBeat watchlists, some other companies that GRAIL investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Last Earnings8/12/2025Today9/01/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryHealthcare Current SymbolNASDAQ:GRAL Previous SymbolNASDAQ:GRAL CIK1699031 WebN/A Phone(650) 771-9796FaxN/AEmployees1,360Year FoundedN/APrice Target and Rating Average Price Target for GRAIL$31.50 High Price Target$43.00 Low Price Target$20.00 Potential Upside/Downside-3.9%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($13.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.03 billion Net Margins-329.86% Pretax Margin-445.82% Return on Equity-16.64% Return on Assets-14.02% Debt Debt-to-Equity RatioN/A Current Ratio9.23 Quick Ratio9.23 Sales & Book Value Annual Sales$134.29 million Price / Sales8.80 Cash Flow$28.76 per share Price / Cash Flow1.14 Book Value$74.50 per share Price / Book0.44Miscellaneous Outstanding Shares36,048,000Free FloatN/AMarket Cap$1.18 billion OptionableOptionable Beta3.20 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:GRAL) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRAIL, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GRAIL With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.